Target intelligence / Profile preview

Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A (PDE11A)

Target
PDE11A
Molecular classification
Enzyme, Hydrolase, Phosphodiesterase
01

Overview

Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A (PDE11A) is a dual-specificity enzyme that catalyzes the hydrolysis of both cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) into their inactive 5'-monophosphate forms. By regulating the intracellular concentrations of these critical second messengers, PDE11A plays a key role in signal transduction pathways governing endocrine function, spermatogenesis, cell proliferation, and neural processes such as social memory formation and mood stabilization. The enzyme is expressed in a tissue-restricted manner, with notable expression in the prostate, testis, adrenal gland, and the hippocampus of the brain. Mutations and dysregulation of PDE11A are clinically linked to endocrine disorders, including Cushing's disease, isolated micronodular adrenocortical disease, and various tumors such as testicular and prostate cancers. In the central nervous system, age-related increases in PDE11A expression in the hippocampus lead to liquid-liquid phase separation (LLPS) and the formation of filamentous structures known as 'ghost axons,' which contribute to age-related cognitive decline. While there are currently no approved selective PDE11A inhibitors, the approved PDE5 inhibitor tadalafil exhibits significant off-target inhibition of PDE11A. Recent drug discovery efforts have focused on developing highly selective, brain-penetrant PDE11A inhibitors (such as the SMQ and MLG series) to reverse LLPS, reduce neuroinflammation, and treat cognitive disorders like Alzheimer's disease and age-related dementia.

Other names
Phosphodiesterase 11APDE11APPNAD2Dual 3',5'-cyclic phosphodiesterase 11A
02

Mechanism of action

Inhibition of cAMP and cGMP hydrolysis

03

Biological functions

Signal transductionRegulation of intracellular cAMP/cGMP levelsSpermatogenesisSocial memory formationMood stabilizationCell proliferation
04

Disease associations

Cushing's diseaseAdrenocortical hyperplasiaTumorigenesisProstate cancerTesticular cancerCognitive declineDementiaAlzheimer's diseaseDepressionAnxietySchizophrenia
05

Safety considerations

Spermatogenesis impairmentFertility issuesAdrenal hyperplasiaCushing's disease riskOff-target effects from other PDE inhibitors
06

Interacting drugs

8 more in the full profile.

07

Biomarkers

PDE11A4 liquid-liquid phase separation (LLPS)PDE11A4 ghost axonsIntracellular cAMP levelsIntracellular cGMP levels

Beyond the preview

Go deeper on Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A (PDE11A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A (PDE11A).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call